Just not clear to me what "various solid tumors" extends to?
The list of such cancers hasn’t been determined yet, IMO. The phase-1 portion of the trial (which is to determine dosing) will probably accept patients with any of the various solid cancers where PD-1 drugs have shown activity. The cancer types included in the phase-1b portion of the trial may be dictated, in part, by the data from the phase-1 portion.
News 
Market Data 
Discover 
